no.645 vol.63 no.645 63 1 645 ACP ACP f CODE CN1645
TRUTH SEEKING
ATM INDEX NATURE REVIEWS DRUG DISCOVERY, VOLUME12, DECEMBER (2013) 2014 Access to Medicine Index. Access to Medicine Foundation
3 CLINICIAN Ê16 NO. 645
CLINICIAN Ê16 NO. 645 4
5 CLINICIAN Ê16 NO. 645
CLINICIAN Ê16 NO. 645 6
7 CLINICIAN Ê16 NO. 645
CLINICIAN Ê16 NO. 645 8
9 CLINICIAN Ê16 NO. 645
CLINICIAN Ê16 NO. 645 10 inph inph inph inph possible inph possible inph probable inph possible inph probable inph definite inph
11 CLINICIAN Ê16 NO. 645 inph Hirono N, et al:distinctive neurobehavioral features among neurodegenerative dementias. J Neuropsychiatry Clin Neurosci, 11, 498-503 DESH inph
585-594 (2015) 2):an open-label randomised trial. Lancet Neurol, 14, idiopathic normal pressure hydrocephalus (SINPHONI- Kazui H, et al:lumboperitoneal shunt surgery for 64-69 (2013) hydrocephalus after shunt surgery. J Neurol Sci, 328, symptoms in patients with idiopathic normal pressure Kazui H, et al : Predictors of the disappearance of triad Brain and Nerve Neurologia medico-chirurgica, 52, 775-809 (2012) normal pressure hydrocephalus :second edition. Mori E, et al : Guidelines for management of idiopathic (2013) multiple hospitals. Int Psychogeriatr, 25, 1365-1373 symptoms in patients with dementia : a cohort study in stay for the treatment of severe neuropsychiatric Sugiyama H, et al :Predictors of prolonged hospital (1999) CLINICIAN Ê16 NO. 645 12
13 CLINICIAN Ê16 NO. 645
CLINICIAN Ê16 NO. 645 14
CT DVD NST /ARB FAX 15 CLINICIAN Ê16 NO. 645
M M CT scan CT ECG CT CT ECG CLINICIAN Ê16 NO. 645 16
17 CLINICIAN Ê16 NO. 645 Hand book,
CLINICIAN Ê16 NO. 645 18 inform inform
19 CLINICIAN Ê16 NO. 645.. mg mg mg mg.. mmhg mmhg 180/110
CLINICIAN Ê16 NO. 645 20 Brose M, et al:sorafenib in radioactive iodinerefractory, locally advanced or metastatic differentiated thyroid cancer :a randomized, double-blind, phase 3 trial. Lancet, 384 (9940), 319-328 (2014) Schlumberger M, et al :Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Eng J Med, 372 (7), 621-630 (2015) http://www.jsmo.or.jp/thyroid-chemo/ Team Nexavar
21 CLINICIAN Ê16 NO. 645 Advance Care Planning
CLINICIAN Ê16 NO. 645 22
23 CLINICIAN Ê16 NO. 645
CLINICIAN Ê16 NO. 645 24
25 CLINICIAN Ê16 NO. 645
CLINICIAN Ê16 NO. 645 26
27 CLINICIAN Ê16 NO. 645
CLINICIAN Ê16 NO. 645 28 high resolution manometry
29 CLINICIAN Ê16 NO. 645
CLINICIAN Ê16 NO. 645 30 2 2 2 Yoshikawa H, et al:oral symptoms including dental erosion in gastroesophageal reflux disease are associated with decreased salivary flow volume and swallowing function. J Gastroenterol, 47, 412-420 (2012) Adachi K, et al :Predominant nocturnal acid reflux in patients with Los Angeles grade C and D reflux esophagitis. J Gastroenterol Hepatol, 16, 1191-1196 (2001) Mizuta A, et al:different sex-related influences of eating habits on the prevalence of reflux esophagitis in Japanese. J Gastroenterol Hepatol, 26, 1060-1064 (2011)
31 CLINICIAN Ê16 NO. 645 Nutritional Support Team Inflammatory bowel disease
CLINICIAN Ê16 NO. 645 32
33 CLINICIAN Ê16 NO. 645
CLINICIAN Ê16 NO. 645 34 IBD IBD IBD IBD IBD 2030
35 CLINICIAN Ê16 NO. 645
CLINICIAN Ê16 NO. 645 36 Treat to Target csdmard
37 CLINICIAN Ê16 NO. 645 csdmard csdmard MSW RA
CLINICIAN Ê16 NO. 645 38
39 CLINICIAN Ê16 NO. 645
CLINICIAN Ê16 NO. 645 40 benefit pt-global-vas unmet medical needs
41 CLINICIAN Ê16 NO. 645
CLINICIAN Ê16 NO. 645 42
43 CLINICIAN Ê16 NO. 645 0 0
CLINICIAN Ê16 NO. 645 44
45 CLINICIAN Ê16 NO. 645 Interdisciplinary http://www.jspc.gr.jp/yogosyu.html
CLINICIAN Ê16 NO. 645 46 Barsky AJ, Borus JF:Functional somatic syndromes. Ann Intern Med, 130 (11), 910-921 (1999) Del Fabbro E : Assessment and management of chemical coping in patients with cancer. JCO, 32, 1734-1738 (2014)
47 CLINICIAN Ê16 NO. 645
CLINICIAN Ê16 NO. 645 48
49 CLINICIAN Ê16 NO. 645
CLINICIAN Ê16 NO. 645 50
51 CLINICIAN Ê16 NO. 645
CLINICIAN Ê16 NO. 645 52
53 CLINICIAN Ê16 NO. 645
CLINICIAN Ê16 NO. 645 54
55 CLINICIAN Ê16 NO. 645
CLINICIAN Ê16 NO. 645 56
57 CLINICIAN Ê16 NO. 645
CLINICIAN Ê16 NO. 645 58 rt-pa Drip, Ship and Retrieve
59 CLINICIAN Ê16 NO. 645 mrs:modified Rankin Scale, FIM:Functional Independence Measure, BI:Barthel Index, NIHSS: National Institute of Health Stroke Scale, JCS:Japan Coma Scale
CLINICIAN Ê16 NO. 645 60
61 CLINICIAN Ê16 NO. 645 No. http://www.city.fukuoka.med.or.jp/
CLINICIAN Ê16 NO. 645 62
63 CLINICIAN Ê16 NO. 645 Hurthle mci....., p<. Hurthle mci....., p<.
CLINICIAN Ê16 NO. 645 64
65 CLINICIAN Ê16 NO. 645 http:// www.jsmo.or.jp/thyroid-chemo/
CLINICIAN Ê16 NO. 645 66 Brose MS, et al:sorafenib in radioactive iodinerefractory, locally advanced or metastatic differentiated thyroid cancer:a randomised, double-blind, phase 3 trial. Lancet, 384, 319-328 (2014) Schlumberger M, et al:lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer. N Engl J Med, 372, 621-630 (2015) http://www.jsmo.or.jp/thyroid-chemo/
67 CLINICIAN Ê16 NO. 645
CLINICIAN Ê16 NO. 645 68
69 CLINICIAN Ê16 NO. 645
②超音波検査 US 数の年度別推移 㻝㻥㻥㻡 㻝㻝㻘㻤㻝㻞 㻝㻥㻥㻢 㻝㻟㻘㻢㻣㻡 㻝㻥㻥㻣 㻝㻠㻘㻤㻤㻝 㻝㻥㻥㻤 㻝㻢㻘㻞㻤㻡 㻝㻥㻥㻥 㻝㻣㻘㻡㻥㻢 㻞㻜㻜㻜 㻝㻤㻘㻝㻤㻢 㻞㻜㻜㻝 㻞㻜㻘㻜㻟㻞 㻞㻜㻜㻞 㻞㻜㻘㻢㻞㻢 㻞㻜㻜㻟 㻞㻞㻘㻡㻣㻡 㻞㻜㻜㻠 㻞㻟㻘㻣㻤㻠 㻞㻜㻜㻡 㻞㻠㻘㻥㻞㻝 㻞㻜㻜㻢 㻞㻠㻘㻝㻥㻜 㻞㻜㻜㻣 㻞㻡㻘㻝㻡㻠 㻞㻜㻜㻤 㻞㻠㻘㻢㻟㻡 㻞㻜㻜㻥 㻞㻠㻘㻥㻟㻣 㻞㻜㻝㻜 㻞㻠㻘㻝㻞㻣 㻞㻜㻝㻝 㻞㻠㻘㻥㻞㻣 㻞㻜㻝㻞 㻞㻠㻘㻜㻣㻝 㻞㻜㻝㻟 㻞㻠㻘㻝㻜㻠 㻞㻜㻝㻠 㻞㻞㻘㻞㻥㻣 年 2004年以降はプラトーである ③細胞診検査数の年度別推移 㻝㻥㻥㻡 㻥㻜㻜 㻝㻥㻥㻢 㻝㻘㻜㻞㻝 㻝㻥㻥㻣 㻝㻘㻝㻠㻢 㻝㻥㻥㻤 㻝㻘㻝㻞㻟 㻝㻥㻥㻥 㻝㻘㻞㻞㻠 㻞㻜㻜㻜 㻝㻘㻜㻢㻠 㻞㻜㻜㻝 㻝㻘㻝㻢㻝 㻞㻜㻜㻞 㻝㻘㻜㻡㻝 㻞㻜㻜㻟 㻝㻘㻝㻡㻝 㻞㻜㻜㻠 㻝㻘㻝㻟㻝 㻞㻜㻜㻡 㻝㻘㻞㻠㻞 㻞㻜㻜㻢 㻝㻘㻝㻞㻜 㻞㻜㻜㻣 㻝㻘㻜㻢㻢 㻞㻜㻜㻤 㻝㻘㻜㻣㻡 㻞㻜㻜㻥 㻝㻘㻜㻟㻜 㻞㻜㻝㻜 㻥㻟㻣 㻞㻜㻝㻝 㻝㻘㻜㻝㻜 㻞㻜㻝㻞 㻥㻟㻣 㻞㻜㻝㻟 㻤㻢㻟 㻞㻜㻝㻠 㻤㻝㻣 年 2005年をピークに減少傾向にある これは針生検 CNB やマンモトーム MMT 検査の 増加によるものである (72) CLINICIAN Ê16 NO. 645 70
71 CLINICIAN Ê16 NO. 645 LH-
CLINICIAN Ê16 NO. 645 72 RH agonist tachyphylaxis
73 CLINICIAN Ê16 NO. 645
CLINICIAN Ê16 NO. 645 74 News letter News letter
75 CLINICIAN Ê16 NO. 645
CLINICIAN Ê16 NO. 645 76
77 CLINICIAN Ê16 NO. 645
CLINICIAN Ê16 NO. 645 78
79 CLINICIAN Ê16 NO. 645
CLINICIAN Ê16 NO. 645 80
81 CLINICIAN Ê16 NO. 645
CLINICIAN Ê16 NO. 645 82
83 CLINICIAN Ê16 NO. 645 1.53.0 5.49 1 2 3 4 5 6 1 2 3 4 5 6 1.53.0
CLINICIAN Ê16 NO. 645 84 0 1 2 3 4 5 4 3 2 1
85 CLINICIAN Ê16 NO. 645 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
CLINICIAN Ê16 NO. 645 86
87 CLINICIAN Ê16 NO. 645
CLINICIAN Ê16 NO. 645 88 End of Life care
89 CLINICIAN Ê16 NO. 645
CLINICIAN Ê16 NO. 645 90 Step 1 Step 5 Step 5
91 CLINICIAN Ê16 NO. 645
CLINICIAN Ê16 NO. 645 92
93 CLINICIAN Ê16 NO. 645
CLINICIAN Ê16 NO. 645 94
95 CLINICIAN Ê16 NO. 645
CLINICIAN Ê16 NO. 645 96 NHS End of Life Care Programme publication supported by NCPC :Advance Care Planning :A Guide for Health and Social Care Staff (2007) http://www.ncpc.org.uk/sites/default/files/ AdvanceCarePlanning.pdf http://citaikyo.jp/other/pdf/20140303_acp_tebiki.pdf http://citaikyo.jp/other/pdf/20140303_acp_enquete.pdf
IBD 3I survey IBD RA RA RA conventional synthetic DMARDscsDMARDs 2015 SpA PsA JIA 97 CLINICIAN Ê16 NO. 645
CLINICIAN Ê16 NO. 645 98 Halichondrin B
99 CLINICIAN Ê16 NO. 645 VEHERI
CLINICIAN Ê16 NO. 645 100
101 CLINICIAN Ê16 NO. 645 in vitro
CLINICIAN Ê16 NO. 645 102 Cortes J, et al : Eribulin monotherapy versus treatment of physician s choice in patients with metastatic breast cancer (EMBRACE) : a phase 3 open-label randomised study. Lancet, 377 (9769), 914-923 (2011) Ali AM, Ueno T, et al :Determining circulating endothelial cells using CellSearch system during preoperative systemic chemotherapy in breast cancer patients. Eur J Cancer, 47 (15), 2265-2272 (2011) Shaked Y, et al :Rapid chemotherapy-induced acute endothelial progenitor cell mobilization:implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell, 14 (3), 263-273 (2008) Tozer GM, et al :Disrupting tumour blood vessels. Nat Rev Cancer, 5 (6), 423-435 (2005) Funahashi Y, et al:eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models. Cancer Sci, 105 (10), 1334-1342 (2014) Kajiyama H, et al:chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. Int J Oncol, 31 (2), 277-283 (2007) Li QQ, et al:twist1-mediated adriamycin-induced epithelial-mesenchymal transition relates to multidrug resistance and invasive potential in breast cancer cells. Clin Cancer Res, 15 (8), 2657-2665 (2009) Yoshida T, et al:eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition
signaling. J Biol Chem, 284 (34), 22825-22833 (2009) activation of urokinase receptor-dependent cell transition (EMT) induced in breast cancer cells by Jo M, et al:reversibility of epithelial-mesenchymal 305 (2008) 1alpha promotes metastasis. Nat Cell Biol, 10 (3), 295- Yang MH, et al :Direct regulation of TWIST by HIF- (MET) states. Br J Cancer, 110 (6), 1497-1505 (2014) 103 CLINICIAN Ê16 NO. 645
CLINICIAN Ê16 NO. 645 104 response rate progression-free survival overall survival quality of life
105 CLINICIAN Ê16 NO. 645 luminal vascular endothelial growth factor P<0.0001 log-rank P=0.1374 positive study
CLINICIAN Ê16 NO. 645 106 survival post-progression post-progression survival P=0.03 log-rank
107 CLINICIAN Ê16 NO. 645 P=0.01 log-rank response evaluation criteria in solid tumours
CLINICIAN Ê16 NO. 645 108 Seah DS, et al :Use and duration of chemotherapy in patients with metastatic breast cancer according to tumor subtype and line of therapy. J Natl Compr Canc Netw, 12 (1), 71-80 (2014) Miller K, et al:paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med, 357, 2666-2676 (2007) Broglio KR, Berry DA:Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst, 101 (23), 1642-1649 (2009) Cortes J, et al : Eribulin monotherapy versus treatment of physician s choice in patients with metastatic breast cancer (EMBRACE):a phase 3 open-label randomised study. Lancet, 377, 914-923 (2011) Twelves C, et al :Efficacy of eribulin in women with metastatic breast cancer:a pooled analysis of two phase 3 studies. Breast Cancer Res Treat, 148 (3), 553-561 (2014) Watanabe J:Eribulin monotherapy improved survivals in patients with ER-positive HER2-negative metastatic breast cancer in the real world:a single institutional review. SpringerPlus, 4, 625 (2015)
CLINICIAN Ê16 NO. 645 114